Molecules:传统中医药参芪通过调控肥大细胞脱粒和Th1/Th2细胞因子平衡对抗过敏性鼻炎的影响

2017-04-06 AlexYang MedSci原创

参芪是一种传统的中草药,并且被广泛的用于对过敏性鼻炎(AR)的治疗。最近,研究人员对参芪的抗过敏性鼻炎的活性和其潜在的分子机制进行了研究。研究人员将卵清蛋白(OVA)诱导的过敏性鼻炎小鼠模型用来评估参芪的抗过敏性鼻炎活性,并利用小鼠嗜碱性白血病(RBL-2H3)细胞来检测参芪对免疫球蛋白E调控的细胞脱粒的影响。研究人员通过分离脾脏淋巴球,并通过蛋白免疫印迹技术检测转录因子和ELISA技术检测细胞因

参芪是一种传统的中草药,并且被广泛的用于对过敏性鼻炎(AR)的治疗。最近,研究人员对参芪的抗过敏性鼻炎的活性和其潜在的分子机制进行了研究。

研究人员将卵清蛋白(OVA)诱导的过敏性鼻炎小鼠模型用来评估参芪的抗过敏性鼻炎活性,并利用小鼠嗜碱性白血病(RBL-2H3)细胞来检测参芪对免疫球蛋白E调控的细胞脱粒的影响。研究人员通过分离脾脏淋巴球,并通过蛋白免疫印迹技术检测转录因子和ELISA技术检测细胞因子((IL-4 and IFN-γ)水平来调查参芪的抗过敏性鼻炎的作用。研究人员发现,在OVA诱导的AR小鼠模型中,参芪减轻了过敏性鼻炎的症状,抑制了鼻粘膜的组织病理学变化,并且减少了IL-4 和IgE的水平。体外实验研究结果确定了参芪可以抑制肥大细胞脱粒作用。更深一步的是,研究人员发现,GATA3, T-bet, p-STAT6, 和 SOCS1的表达和IFN-γ and IL-4 的产生表明了参芪可以在OVA诱导的脾脏淋巴球中平衡Th1/Th2的比例。总之,研究指出,这些结果表明了参芪可抑制肥大细胞调控的过敏反应和改善过敏性鼻炎中Th1/Th2的平衡,具有明显的抗过敏性鼻炎活性,。

原始出处:

Shao YY, Zhou YM, Hu M et al. The Anti-Allergic Rhinitis Effect of Traditional Chinese Medicine of Shenqi by Regulating Mast Cell Degranulation and Th1/Th2 Cytokine Balance. Molecules. 22 March 2017.  doi: 10.3390/molecules22030504.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1809541, encodeId=f8c3180954150, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Oct 26 10:00:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046817, encodeId=1b75204681e10, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Sep 19 00:00:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049570, encodeId=f30c20495e0ea, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Sep 18 21:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186040, encodeId=16e8186040aa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/22/9492b0bdd3ebdf662ab1cde6e8473dca.jpg, createdBy=0f261679513, createdName=万里江山一孤舟, createdTime=Sat Apr 08 21:11:09 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283575, encodeId=bd1312835e530, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408874, encodeId=442314088e4a6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569175, encodeId=bb3f15691e59b, content=<a href='/topic/show?id=13288188450' target=_blank style='color:#2F92EE;'>#肥大细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81884, encryptionId=13288188450, topicName=肥大细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c92315497125, createdName=gds2014, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1809541, encodeId=f8c3180954150, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Oct 26 10:00:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046817, encodeId=1b75204681e10, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Sep 19 00:00:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049570, encodeId=f30c20495e0ea, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Sep 18 21:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186040, encodeId=16e8186040aa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/22/9492b0bdd3ebdf662ab1cde6e8473dca.jpg, createdBy=0f261679513, createdName=万里江山一孤舟, createdTime=Sat Apr 08 21:11:09 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283575, encodeId=bd1312835e530, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408874, encodeId=442314088e4a6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569175, encodeId=bb3f15691e59b, content=<a href='/topic/show?id=13288188450' target=_blank style='color:#2F92EE;'>#肥大细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81884, encryptionId=13288188450, topicName=肥大细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c92315497125, createdName=gds2014, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1809541, encodeId=f8c3180954150, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Oct 26 10:00:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046817, encodeId=1b75204681e10, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Sep 19 00:00:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049570, encodeId=f30c20495e0ea, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Sep 18 21:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186040, encodeId=16e8186040aa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/22/9492b0bdd3ebdf662ab1cde6e8473dca.jpg, createdBy=0f261679513, createdName=万里江山一孤舟, createdTime=Sat Apr 08 21:11:09 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283575, encodeId=bd1312835e530, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408874, encodeId=442314088e4a6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569175, encodeId=bb3f15691e59b, content=<a href='/topic/show?id=13288188450' target=_blank style='color:#2F92EE;'>#肥大细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81884, encryptionId=13288188450, topicName=肥大细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c92315497125, createdName=gds2014, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1809541, encodeId=f8c3180954150, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Oct 26 10:00:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046817, encodeId=1b75204681e10, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Sep 19 00:00:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049570, encodeId=f30c20495e0ea, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Sep 18 21:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186040, encodeId=16e8186040aa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/22/9492b0bdd3ebdf662ab1cde6e8473dca.jpg, createdBy=0f261679513, createdName=万里江山一孤舟, createdTime=Sat Apr 08 21:11:09 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283575, encodeId=bd1312835e530, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408874, encodeId=442314088e4a6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569175, encodeId=bb3f15691e59b, content=<a href='/topic/show?id=13288188450' target=_blank style='color:#2F92EE;'>#肥大细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81884, encryptionId=13288188450, topicName=肥大细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c92315497125, createdName=gds2014, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
    2017-04-08 万里江山一孤舟

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1809541, encodeId=f8c3180954150, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Oct 26 10:00:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046817, encodeId=1b75204681e10, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Sep 19 00:00:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049570, encodeId=f30c20495e0ea, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Sep 18 21:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186040, encodeId=16e8186040aa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/22/9492b0bdd3ebdf662ab1cde6e8473dca.jpg, createdBy=0f261679513, createdName=万里江山一孤舟, createdTime=Sat Apr 08 21:11:09 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283575, encodeId=bd1312835e530, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408874, encodeId=442314088e4a6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569175, encodeId=bb3f15691e59b, content=<a href='/topic/show?id=13288188450' target=_blank style='color:#2F92EE;'>#肥大细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81884, encryptionId=13288188450, topicName=肥大细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c92315497125, createdName=gds2014, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1809541, encodeId=f8c3180954150, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Oct 26 10:00:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046817, encodeId=1b75204681e10, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Sep 19 00:00:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049570, encodeId=f30c20495e0ea, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Sep 18 21:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186040, encodeId=16e8186040aa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/22/9492b0bdd3ebdf662ab1cde6e8473dca.jpg, createdBy=0f261679513, createdName=万里江山一孤舟, createdTime=Sat Apr 08 21:11:09 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283575, encodeId=bd1312835e530, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408874, encodeId=442314088e4a6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569175, encodeId=bb3f15691e59b, content=<a href='/topic/show?id=13288188450' target=_blank style='color:#2F92EE;'>#肥大细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81884, encryptionId=13288188450, topicName=肥大细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c92315497125, createdName=gds2014, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]
    2017-04-07 cathymary
  7. [GetPortalCommentsPageByObjectIdResponse(id=1809541, encodeId=f8c3180954150, content=<a href='/topic/show?id=6cd683e603b' target=_blank style='color:#2F92EE;'>#胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83760, encryptionId=6cd683e603b, topicName=胞因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Oct 26 10:00:00 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046817, encodeId=1b75204681e10, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Sep 19 00:00:00 CST 2017, time=2017-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049570, encodeId=f30c20495e0ea, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Sep 18 21:00:00 CST 2017, time=2017-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186040, encodeId=16e8186040aa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/03/22/9492b0bdd3ebdf662ab1cde6e8473dca.jpg, createdBy=0f261679513, createdName=万里江山一孤舟, createdTime=Sat Apr 08 21:11:09 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1283575, encodeId=bd1312835e530, content=<a href='/topic/show?id=2c00e784416' target=_blank style='color:#2F92EE;'>#细胞因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77844, encryptionId=2c00e784416, topicName=细胞因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408874, encodeId=442314088e4a6, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569175, encodeId=bb3f15691e59b, content=<a href='/topic/show?id=13288188450' target=_blank style='color:#2F92EE;'>#肥大细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81884, encryptionId=13288188450, topicName=肥大细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c92315497125, createdName=gds2014, createdTime=Fri Apr 07 15:00:00 CST 2017, time=2017-04-07, status=1, ipAttribution=)]

相关资讯

JAMA子刊:韩国民众患慢性鼻窦炎、过敏性鼻炎和鼻中隔偏差的发病率及风险因素探究

背景慢性鼻窦炎(CRS)、过敏性鼻炎(AR)和鼻中隔偏差(NSD)这些频繁发生的慢性疾病要消耗相当大的医疗资源并增加民众的经济负担。 目的该研究的目的在于确定韩国民众患慢性鼻窦炎(CRS)、过敏性鼻炎(AR)和鼻中隔偏差(NSD)的患病率和相关风险因素。 设计研究人员从2008-2012年韩国国家健康和营养调查研究(KNHANES)中提取出相关数据进行分析。共有35511参与者接受访谈,主要内容为

J Periodontol:长知识!过敏性鼻炎可增加牙周炎的发病风险

J Periodontol:长知识!过敏性鼻炎可增加牙周炎的发病风险关于鼻部疾病与牙周炎之间的关联鲜为人知。本研究旨在探究牙周炎与既往过敏性鼻炎(AR)之间的关联。采用病例对照研究设计,研究数据来源于台湾的纵向健康保险数据库2000,匹配了研究数据。研究共纳入了71182名慢性牙周炎患者作为病例组,和71182名非牙周炎人群作为对照组。使用广义线性混合模型分析来计算病例组和对照组既往AR的比值比和

JAMA:舌下草花粉免疫治疗对过敏性鼻炎真的有用么?

舌下免疫治疗和皮下免疫治疗在季节性过敏性鼻炎中有一定疗效。皮下免疫和舌下免疫连续治疗三年,至少可以改善治疗后2年的症状。近期,一项发表在权威杂志JAMA上的研究旨在评估使用草花粉舌下免疫治疗2年能否改善3年的鼻应答过敏反应。这是一项随机双盲安慰剂对照试验,3个平行组研究在伦敦帝国理工学院的单一学术中心进行,试验对象为中度至重度季节性过敏性鼻炎成人患者(干扰日常活动或睡眠)。第一次招募时间是2011

指南专题:变应性鼻炎如何诊断与治疗?答案在这里!

最是一年春好处,阳春三月正是外出春游赏花的好时节。然而,对于过敏性鼻炎的患者来说,却是一年中最无法言说的痛:整日顶着通红的鼻头,不停打着喷嚏,擦着鼻涕,“赏春”变成了“伤春”! 每到现在的这个季节,门诊的过敏性鼻炎患者会激增,大多数患者都是外出时吸入过敏源所导致的季节性过敏性鼻炎。过敏性鼻炎又称变应性鼻炎,它的发生需要同时具备三个条件,即特应性个体(过敏体质的人)、过敏源(主要包括花粉、植物毛絮

J Allergy Clin Immunol:过敏性鼻炎的预测因子

过敏性鼻炎(AR)是最常见的慢性疾病之一,是指特应性个体接触变应原后,主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病,通常在20岁前发病。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。但是目前由于缺乏长期的前瞻性研究,因此临床上关于该疾病的信息预测、风险情况和保护因素等资料依旧匮乏。Grabenhenrich LB等人就该问题进

关注哮喘、过敏性鼻炎的个体化治疗

重症哮喘管理最新进展    来自英国伦敦帝国理工学院实验医学、国家心肺研究所钟建桓教授,其对2014年欧洲呼吸协会(ERS)/美国胸科协会(ATS)国际指南关于重症哮喘管理方面的重点信息进行介绍。 ①进一步优化吸入型糖皮质激素(ICS)/长效β2受体激动剂(LABA)的剂量,可考虑更高剂量的治疗性试验。②考虑应用低剂量口服糖皮质激素进行维持治疗,但需监测